Tijana Stanković

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

Zorica Milošević, Milica Pešić, Tijana Stanković et al. · Translational research · 2014 · 55 citations

Anaplastic Thyroid Carcinoma, Signaling Pathway, Medicine +7

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma

Miodrag Dragoj, Zorica Milošević, Jasna Banković et al. · Cellular Oncology · 2016 · 43 citations

Doxorubicin Resistance, Medicine, Pathology +9

A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor

Anna Lucia Fallacara, Claudio Zamperini, Ana Podolski-Renić et al. · Cancers · 2019 · 43 citations · Full text

Cytotoxic Activity of Royleanone Diterpenes from <i>Plectranthus madagascariensis</i> Benth

Diogo Matias, Marisa Nicolai, Lucı́lia Saraiva et al. · ACS Omega · 2019 · 40 citations · Full text

Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing

Ana Podolski-Renić, Milka Jadranin, Tijana Stanković et al. · Cancer Chemotherapy and Pharmacology · 2013 · 36 citations

New Compounds, Oncology, Cytogenetic Changes +10